Читать книгу Pathy's Principles and Practice of Geriatric Medicine - Группа авторов - Страница 628

In general, lower‐risk MDS patients have been offered supportive care only, especially older adults, as the risk/benefit profile of most active disease‐modifying agents is considered unfavourable. However, newer, less‐toxic agents can be considered in the future even in vulnerable patients, mainly in those with refractory symptoms or higher risk of progression to AML.